Neurogene Inc. (NGNE)

USD 10.89

(-1.0%)

Market Cap (In USD)

162.58 Million

Revenue (In USD)

-

Net Income (In USD)

-36.31 Million

Avg. Volume

279.55 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
14.01-74.49
PE
-2.54
EPS
-4.28
Beta Value
0.0
ISIN
US64135M1053
CUSIP
64135M105
CIK
1404644
Shares
14929600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rachel L. McMinn Ph.D.
Employee Count
-
Website
https://www.neurogene.com
Ipo Date
2014-03-07
Details
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.